Steven Cohen's FATE Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.53 M shares of Fate Therapeutics, Inc. (FATE) worth $1.5 M, representing 0.00% of the portfolio. First purchased in 2019-Q1, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in FATE, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 3.42 M shares. Largest reduction occurred in Q1 2024, reducing 1.9 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Fate Therapeutics (FATE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Fate Therapeutics (FATE) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1.53 M | New Buy | 1.53 M | $0.98 |
| Q2 2024 | -1.58 M | Sold Out | 0 | $0.00 |
| Q1 2024 | -1.9 M | Reduce 54.59% | 1.58 M | $7.34 |
| Q4 2023 | +3.42 M | Add 4653.56% | 3.49 M | $3.74 |
| Q3 2023 | +63,265 | Add 624.16% | 73,401 | $2.12 |
| Q2 2023 | +10,136 | New Buy | 10,136 | $4.76 |
| Q4 2020 | -151,564 | Sold Out | 0 | $0.00 |
| Q3 2020 | -175,272 | Reduce 53.63% | 151,564 | $39.97 |
| Q2 2020 | +326,836 | New Buy | 326,836 | $34.31 |
| Q1 2020 | -782,783 | Sold Out | 0 | $0.00 |
| Q4 2019 | -397,306 | Reduce 33.67% | 782,783 | $19.57 |
| Q3 2019 | +586,589 | Add 98.84% | 1.18 M | $15.53 |
| Q2 2019 | +93,500 | Add 18.70% | 593,500 | $20.30 |
| Q1 2019 | +500,000 | New Buy | 500,000 | $17.57 |
Steven Cohen's Fate Therapeutics Investment FAQs
Steven Cohen first purchased Fate Therapeutics, Inc. (FATE) in Q1 2019, acquiring 500,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Fate Therapeutics, Inc. (FATE) for 14 quarters since Q1 2019.
Steven Cohen's largest addition to Fate Therapeutics, Inc. (FATE) was in Q4 2023, adding 3,489,163 shares worth $13.05 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,527,986 shares of Fate Therapeutics, Inc. (FATE), valued at approximately $1.5 M.
As of the Q4 2025 filing, Fate Therapeutics, Inc. (FATE) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Fate Therapeutics, Inc. (FATE) was 3,489,163 shares, as reported at the end of Q4 2023.